$CRIS
CURIS INC Stock $cris

$cris Overview Financials Valuation SEC Filings Company Website

2014 Q4 Form 10-Q Financial Statement

#000119312514404759 Filed on November 10, 2014

Income Statement

Concept	2014 Q4	2014 Q3	2013 Q3
Revenue	$1.993M	$1.765M	$7.202M
YoY Change	30.74%	-75.5%	1146.55%
Cost Of Revenue	$90.00K	$90.00K	$50.00K
YoY Change	28.57%	80.0%	150.0%
Gross Profit	$1.900M	$1.680M	$7.150M
YoY Change	31.03%	-76.5%	1176.79%
Gross Profit Margin	95.35%	95.19%	99.28%
Selling, General & Admin	$3.060M	$2.720M	$2.850M
YoY Change	2.68%	-4.56%	15.38%
% of Gross Profit	161.05%	161.9%	39.86%
Research & Development	$3.650M	$3.705M	$4.171M
YoY Change	23.31%	-11.16%	37.08%
% of Gross Profit	192.11%	220.56%	58.33%
Depreciation & Amortization	$50.00K	$40.00K	$30.00K
YoY Change	25.0%	33.33%	0.0%
% of Gross Profit	2.63%	2.38%	0.42%
Operating Expenses	$6.710M	$3.705M	$4.171M
YoY Change	12.96%	-11.16%	37.08%
Operating Profit	-$4.811M	-$4.753M	$130.4K
YoY Change	7.31%	-3745.86%	-102.63%
Interest Expense	-$880.0K	$933.9K	$964.5K
YoY Change	-403.45%	-3.18%	-38.95%
% of Operating Profit			739.86%
Other Income/Expense, Net		-$827.1K	-$1.998M
YoY Change		-58.61%	-226.8%
Pretax Income	-$5.690M	-$5.580M	-$1.870M
YoY Change	35.48%	198.4%	-44.84%
Income Tax		$0.00	$0.00
% Of Pretax Income
Net Earnings	-$5.689M	-$5.580M	-$1.868M
YoY Change	35.51%	198.75%	-44.82%
Net Earnings / Revenue	-285.49%	-316.18%	-25.93%
Basic Earnings Per Share
Diluted Earnings Per Share	-$330.8K	-$324.4K	-$113.4K
COMMON SHARES
Basic Shares Outstanding	86.00M shares	86.00M shares	81.69M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q4	2014 Q3	2013 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$49.80M	$54.60M	$63.20M
YoY Change	-14.43%	-13.61%	53.77%
Cash & Equivalents	$7.747M	$7.933M	$13.78M
Short-Term Investments	$42.00M	$46.70M	$49.40M
Other Short-Term Assets	$500.0K	$700.0K	$500.0K
YoY Change	0.0%	40.0%	0.0%
Inventory
Prepaid Expenses
Receivables	$1.961M	$1.839M	$1.156M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$52.21M	$57.11M	$64.89M
YoY Change	-13.22%	-12.0%	53.77%
LONG-TERM ASSETS
Property, Plant & Equipment	$407.7K	$407.4K	$467.5K
YoY Change	-8.51%	-12.86%	-6.5%
Goodwill	$8.982M	$8.982M	$8.982M
YoY Change	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments	$800.0K	$1.500M	$3.900M
YoY Change	-92.52%	-61.54%	387.5%
Other Assets	$67.54K	$77.56K	$116.9K
YoY Change	-35.08%	-33.66%	-41.54%
Total Long-Term Assets	$10.40M	$11.10M	$13.65M
YoY Change	-49.09%	-18.7%	31.29%
TOTAL ASSETS
Total Short-Term Assets	$52.21M	$57.11M	$64.89M
Total Long-Term Assets	$10.40M	$11.10M	$13.65M
Total Assets	$62.61M	$68.21M	$78.55M
YoY Change	-22.31%	-13.16%	49.33%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.349M	$2.371M	$2.291M
YoY Change	15.33%	3.52%	-15.16%
Accrued Expenses	$2.008M	$1.942M	$1.977M
YoY Change	5.03%	-1.77%	52.07%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$5.710M	$5.522M	$1.450M
YoY Change	118.76%	280.81%
Total Short-Term Liabilities	$10.07M	$9.835M	$5.718M
YoY Change	53.49%	72.01%	42.94%
LONG-TERM LIABILITIES
Long-Term Debt	$22.59M	$23.54M	$29.13M
YoY Change	-19.17%	-19.19%
Other Long-Term Liabilities	$174.0K	$187.4K	$197.9K
YoY Change	-11.55%	-5.3%	-93.18%
Total Long-Term Liabilities	$22.76M	$23.73M	$29.33M
YoY Change	-19.11%	-19.1%	911.37%
TOTAL LIABILITIES
Total Short-Term Liabilities	$10.07M	$9.835M	$5.718M
Total Long-Term Liabilities	$22.76M	$23.73M	$29.33M
Total Liabilities	$32.83M	$33.56M	$36.97M
YoY Change	-7.31%	-9.23%	435.85%
SHAREHOLDERS EQUITY
Retained Earnings	-$779.6M	-$773.9M	-$756.6M
YoY Change	2.46%	2.28%
Common Stock	$810.9M	$872.3K	$853.5K
YoY Change	93016.24%	2.2%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$1.524M	$1.524M	$1.524M
YoY Change	0.0%	0.0%
Treasury Stock Shares	1.223M shares	1.223M shares	1.223M shares
Shareholders Equity	$29.78M	$34.65M	$41.57M
YoY Change
Total Liabilities & Shareholders Equity	$62.61M	$68.21M	$78.55M
YoY Change	-22.31%	-13.16%	49.33%

Cashflow Statement

Concept	2014 Q4	2014 Q3	2013 Q3
OPERATING ACTIVITIES
Net Income	-$5.689M	-$5.580M	-$1.868M
YoY Change	35.51%	198.75%	-44.82%
Depreciation, Depletion And Amortization	$50.00K	$40.00K	$30.00K
YoY Change	25.0%	33.33%	0.0%
Cash From Operating Activities	-$4.690M	-$2.080M	$270.0K
YoY Change	-14.88%	-870.37%	-106.46%
INVESTING ACTIVITIES
Capital Expenditures	-$20.00K	-$10.00K	-$100.0K
YoY Change	0.0%	-90.0%	900.0%
Acquisitions
YoY Change
Other Investing Activities	$5.280M	$690.0K	-$5.960M
YoY Change	-189.34%	-111.58%	341.48%
Cash From Investing Activities	$5.250M	$680.0K	-$6.060M
YoY Change	-188.53%	-111.22%	345.59%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-740.0K	-820.0K	9.820M
YoY Change	-110.21%	-108.35%	679.37%
NET CHANGE
Cash From Operating Activities	-4.690M	-2.080M	270.0K
Cash From Investing Activities	5.250M	680.0K	-6.060M
Cash From Financing Activities	-740.0K	-820.0K	9.820M
Net Change In Cash	-180.0K	-2.220M	4.030M
YoY Change	-95.7%	-155.09%	-194.16%
FREE CASH FLOW
Cash From Operating Activities	-$4.690M	-$2.080M	$270.0K
Capital Expenditures	-$20.00K	-$10.00K	-$100.0K
Free Cash Flow	-$4.670M	-$2.070M	$370.0K
YoY Change	-14.94%	-659.46%	-108.87%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	86004857	shares
CY2013Q3	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	1926465
CY2013Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13778686
CY2014Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	87227703	shares
CY2014Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	86004857	shares
CY2014Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	225000000	shares
CY2014Q3	us-gaap	Treasury Stock Shares TreasuryStockShares	1222846	shares
CY2014Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	3.55
CY2014Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1373517	shares
CY2014Q3	us-gaap	Interest Payable Current InterestPayableCurrent	313452
CY2014Q3	us-gaap	Common Stock Value CommonStockValue	872277
CY2014Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2014Q3	us-gaap	Liabilities Current LiabilitiesCurrent	9834654
CY2014Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2014Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	3464
CY2014Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2371237
CY2014Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-773866425
CY2014Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	5521523
CY2014Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	23626614
CY2014Q3	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1117251
CY2014Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1941894
CY2014Q3	us-gaap	Stockholders Equity StockholdersEquity	34646577
CY2014Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	187420
CY2014Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	195116
CY2014Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	23540461
CY2014Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	68209112
CY2014Q3	us-gaap	Liabilities Fair Value Disclosure Nonrecurring LiabilitiesFairValueDisclosureNonrecurring	0
CY2014Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	809161290
CY2014Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	316075
CY2014Q3	us-gaap	Liabilities Liabilities	33562535
CY2014Q3	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	12222
CY2014Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7933470
CY2014Q3	us-gaap	Goodwill Goodwill	8982000
CY2014Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	407361
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	431000
CY2014Q3	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	46665470
CY2014Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	655765
CY2014Q3	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	152610
CY2014Q3	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	7923
CY2014Q3	us-gaap	Assets Fair Value Disclosure Nonrecurring AssetsFairValueDisclosureNonrecurring	0
CY2014Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	46665470
CY2014Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	431000
CY2014Q3	us-gaap	Deferred Finance Costs Gross DeferredFinanceCostsGross	118182
CY2014Q3	us-gaap	Long Term Investments LongTermInvestments	1481682
CY2014Q3	us-gaap	Assets Assets	68209112
CY2014Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	5514000
CY2014Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1839319
CY2014Q3	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	46661171
CY2014Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	77558
CY2014Q3	us-gaap	Restricted Investments Current RestrictedInvestmentsCurrent	13877
CY2014Q3	us-gaap	Treasury Stock Value TreasuryStockValue	1524029
CY2014Q3	us-gaap	Assets Current AssetsCurrent	57107901
CY2014Q3	cris	Debt Instrument Current Carrying Amount DebtInstrumentCurrentCarryingAmount	5559576
CY2014Q3	cris	Stock Issued During Period Due To Exercise Of Warrants StockIssuedDuringPeriodDueToExerciseOfWarrants	238805	shares
CY2014Q3	cris	Warrant Liability Noncurrent WarrantLiabilityNoncurrent	0
CY2014Q3	cris	Estimated Fair Value Of Warrants EstimatedFairValueOfWarrants	0
CY2010Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1612322	shares
CY2010Q1	cris	Registered Direct Offering Number Of Warrant Per Unit RegisteredDirectOfferingNumberOfWarrantPerUnit	1
CY2010Q1	cris	Registered Direct Offering Number Of Common Stock Per Unit RegisteredDirectOfferingNumberOfCommonStockPerUnit	1
CY2010Q1	cris	Registered Direct Offering Units RegisteredDirectOfferingUnits	6449288	shares
CY2010Q1	cris	Direct Offering Purchase Price DirectOfferingPurchasePrice	2.52
CY2012Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	1488179
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12747709
CY2012Q4	us-gaap	Deferred Finance Costs Gross DeferredFinanceCostsGross	421715
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	87081862	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	85859016	shares
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	225000000	shares
CY2013Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	1222846	shares
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2013Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	716786
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6558517
CY2013Q4	us-gaap	Interest Payable Current InterestPayableCurrent	298935
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	870819
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2013Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-6984
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2036864
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-760826561
CY2013Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	2610174
CY2013Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	28050291
CY2013Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1267954
CY2013Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1911479
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	45173585
CY2013Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	196734
CY2013Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	178390
CY2013Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	27945186
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	80590808
CY2013Q4	us-gaap	Liabilities Fair Value Disclosure Nonrecurring LiabilitiesFairValueDisclosureNonrecurring	0
CY2013Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	806660340
CY2013Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	166200
CY2013Q4	us-gaap	Liabilities Liabilities	35417223
CY2013Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	9046
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9591487
CY2013Q4	us-gaap	Goodwill Goodwill	8982000
CY2013Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	104034
CY2013Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	47592763
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	445655
CY2013Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	47586333
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	495260
CY2013Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	166487
CY2013Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	15476
CY2013Q4	us-gaap	Assets Fair Value Disclosure Nonrecurring AssetsFairValueDisclosureNonrecurring	0
CY2013Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	48588135
CY2013Q4	us-gaap	Certificates Of Deposit At Carrying Value CertificatesOfDepositAtCarryingValue	1001802
CY2013Q4	us-gaap	Deferred Finance Costs Gross DeferredFinanceCostsGross	152496
CY2013Q4	us-gaap	Long Term Investments LongTermInvestments	10726685
CY2013Q4	us-gaap	Assets Assets	80590808
CY2013Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1477188
CY2013Q4	us-gaap	Restricted Investments Current RestrictedInvestmentsCurrent	13877
CY2013Q4	us-gaap	Treasury Stock Value TreasuryStockValue	1524029
CY2013Q4	us-gaap	Assets Current AssetsCurrent	60165947
CY2013Q4	cris	Debt Instrument Current Carrying Amount DebtInstrumentCurrentCarryingAmount	2663677
CY2013Q4	cris	Warrant Liability Noncurrent WarrantLiabilityNoncurrent	716786
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	640000	shares
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.20
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2014Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.019	pure
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.70	pure
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	400000	shares
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.34
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2014Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.021	pure
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.65	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.29
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-4026852
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	81235922	shares
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.10
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11905073	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	2308000
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-13918
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	494616
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-161586
	us-gaap	Licenses Revenue LicensesRevenue	10000000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	126482
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4933192
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8125013
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3190788
	us-gaap	Royalty Revenue RoyaltyRevenue	2549945
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	261475
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	438286
	us-gaap	Revenues Revenues	13477895
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	43908127
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	134457
	us-gaap	Net Income Loss NetIncomeLoss	-8123980
	us-gaap	Investment Income Interest InvestmentIncomeInterest	117585
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	248405
	us-gaap	Interest Expense InterestExpense	2870087
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9965847
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	78605
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	1030977
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	438286
	us-gaap	Interest Costs Incurred Capitalized InterestCostsIncurredCapitalized	753639
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	104359
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	12747243
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3514595
	us-gaap	Royalty Expense RoyaltyExpense	127499
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-7689414
	us-gaap	Proceeds From Sale Of Other Property Plant And Equipment ProceedsFromSaleOfOtherPropertyPlantAndEquipment	0
	us-gaap	Costs And Expenses CostsAndExpenses	18411087
	us-gaap	Paid In Kind Interest PaidInKindInterest	0
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	36339252
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8317741
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	436449
	us-gaap	Share Based Compensation ShareBasedCompensation	2499091
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1955000
	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	4097128
	us-gaap	Proceeds From Repayments Of Debt ProceedsFromRepaymentsOfDebt	0
	cris	Common Stock Offering Cost Including Commission CommonStockOfferingCostIncludingCommission	367706
	cris	Research And Development Revenue ResearchAndDevelopmentRevenue	927950
	cris	Proceeds From At Market Issuance Of Common Stock Net Of Issuance Costs ProceedsFromAtMarketIssuanceOfCommonStockNetOfIssuanceCosts	9494123
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	400000	shares
	dei	Document Type DocumentType	10-Q
	dei	Entity Registrant Name EntityRegistrantName	CURIS INC
	dei	Trading Symbol TradingSymbol	CRIS
	us-gaap	Revenue Recognition Accounting Policy Gross And Net Revenue Disclosure RevenueRecognitionAccountingPolicyGrossAndNetRevenueDisclosure	<div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> In May 2014, the FASB issued guidance codified in ASC 606,<i> Revenue Recognition—Revenue from Contracts with Customers</i>, which amends the guidance in former ASC 605,<i> Revenue Recognition,</i> and is effective for public companies for fiscal years beginning after December 15, 2016. The Company is currently evaluating the impact of the provisions of ASC 606.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> In August 2014, the FASB issued an accounting standards update, <i>Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern, </i>which is included in ASC 205, <i>Presentation of Financial Statements</i>. This update provides an explicit requirement for management to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosure in certain circumstances. The guidance will be effective for fiscal years beginning after December 15, 2016, and applied prospectively; early adoption is also permitted. The Company does not expect adoption of this guidance to have a material impact on its financial condition or results of operations.</p> </div>
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.79
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	us-gaap	Nature Of Operations NatureOfOperations	<div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><b>1.</b></td> <td valign="top" align="left"><b><u>Nature of Business</u></b></td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Curis, Inc. is an oncology-focused company developing novel drug candidates for the treatment of human cancers. As used throughout these consolidated financial statements, the term “the Company” refers to the business of Curis, Inc. and its wholly owned subsidiaries, except where the context otherwise requires, and the term “Curis” refers to Curis, Inc.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The Company conducts its research and development programs both internally and through strategic collaborations. The Company is leveraging its experience in targeting signaling pathways to develop drug candidates including CUDC-907, a dual histone deacetylase, or HDAC and phosphoinositide-3 kinase, or PI3K, inhibitor, and CUDC-427, a small molecule antagonist of the inhibitor of apoptosis, or IAP, proteins. Erivedge®, the first and only approved medicine for the treatment of advanced basal cell carcinoma, or BCC, is being commercialized by F. Hoffmann-La Roche Ltd., or Roche, and Genentech Inc., or Genentech, a member of the Roche Group, under a collaboration agreement between Curis and Genentech.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> In August 2009, the Company granted a worldwide, exclusive royalty-bearing license to develop, manufacture, market and sell its HSP90 inhibitor technology, including Debio 0932, to Debiopharm Group, or Debiopharm. Under the agreement, Debiopharm had assumed all future development responsibility for Debio 0932 and has incurred all costs related to the development of products under the agreement.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> In August 2012, Debiopharm initiated the HALO, or HSP90 inhibition And Lung cancer Outcomes, phase 1/2 clinical trial of Debio 0932 in combination with various chemotherapy regimens in patients with stage IIIb or IV non-small cell lung cancer, or NSCLC without known epidermal growth factor receptor, or EGFR, mutations. The primary objective of this trial is to analyze the effect of adding Debio 0932 to combination chemotherapy with cisplatin/pemetrexed, cisplatin/ gemcitabine or docetaxel on the rate of progression-free survival at 6 months in first-line or second-line therapy of patients in this trial population.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Debiopharm has recently reviewed available data from all three arms of the ongoing phase 1 portion of the HALO study and has determined that it will not advance to the phase 2 stage of the study. Safety observations were generally consistent with the expected side effects of Debio 0932 and/or the respective chemotherapeutic regimens administered in the trial. No new Debio 0932-related side effects were identified. Debiopharm has informed Curis that it will discontinue the phase 1 portion of this study in November 2014.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Debiopharm has indicated that it plans to return the rights to Debio 0932 to the Company and Curis expects to receive formal notice of termination of the licence agreement from Debiopharm. Curis anticipates that the parties will seek to enter into a transition agreement in the fourth quarter of 2014 regarding the orderly return of the program to Curis. While the Company does not plan to continue further study of Debio 0932 in non-small cell lung cancer, it is exploring the potential to test the molecule in other promising indications, either in company-sponsored or investigator sponsored studies.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The Company operates in a single reportable segment, which is the research and development of innovative cancer therapeutics. The Company expects that any products that are successfully developed and commercialized would be used in the health care industry and would be regulated in the United States by the Food and Drug Administration, or FDA, and in overseas markets by similar regulatory authorities.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The Company is subject to risks common to companies in the biotechnology industry as well as risk factors that are specific to the Company’s business, including, but not limited to: the Company’s reliance on Genentech and Roche to successfully commercialize Erivedge in the approved indication of advanced BCC the Company’s ability to advance and expand its research and development programs; the Company’s ability to obtain adequate financing to fund its operations; the ability of the Company’s wholly owned subsidiary, Curis Royalty, LLC, or Curis Royalty, to satisfy the terms of its loan agreement with BioPharma Secured Debt Fund II Sub, S.à r.l., a Luxembourg limited liability company managed by Pharmakon Advisors, or BioPharma-II; the Company’s ability to obtain and maintain necessary intellectual property protection; development by the Company’s competitors of new or better technological innovations; dependence on key personnel; the Company’s ability to comply with regulatory requirements; and the Company’s ability to execute on its overall business strategies.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The Company’s future operating results will largely depend on the magnitude of payments from its current and potential future corporate collaborators and the progress of drug candidates currently in its development pipeline. The results of the Company’s operations will vary significantly from year to year and quarter to quarter and depend on a number of factors, including, but not limited to: Roche and Genentech’s ability to successfully commercialize Erivedge; the timing, outcome and cost of the Company’s preclinical studies and clinical trials for its drug candidates; and the Company’s ability to successfully enter into one or more material licenses or collaboration agreements for its proprietary drug candidates.</p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; MARGIN-TOP: 6px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">  </p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The Company anticipates that existing cash, cash equivalents and investments at September 30, 2014 should enable it to maintain current and planned operations into 2016. The Company’s ability to continue funding its planned operations beyond this period is dependent upon, among other things, the success of its collaborations with Genentech and the Leukemia & Lymphoma Society, or LLS, including its receipt of additional contingent cash payments under these collaborations; its ability to control expenses and its ability to raise additional funds through equity or debt financings, new collaborations or other sources of financing. The Company may not be able to successfully raise additional funds or enter into or continue any corporate collaborations and the timing, amount and likelihood of the Company receiving payments under such collaborations is highly uncertain. If the Company is unable to obtain adequate financing, the Company may be required to reduce or delay spending on its research and/or development programs.</p> </div>
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-12120518
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	1040000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	85962415	shares
	dei	Document Period End Date DocumentPeriodEndDate	2014-09-30
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P60D
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.75
	dei	Entity Central Index Key EntityCentralIndexKey	0001108205
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.15
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12737636	shares
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	Segment
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	2213000
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-13877
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	91973
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-108511
	us-gaap	Repayments Of Debt RepaymentsOfDebt	4279156
	us-gaap	Licenses Revenue LicensesRevenue	3000000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	168343
	us-gaap	Operating Income Loss OperatingIncomeLoss	-11051161
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	1750
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13029416
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1988703
	us-gaap	Royalty Revenue RoyaltyRevenue	4895454
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-716786
	us-gaap	Revenues Revenues	7850782
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	38284246
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	65764
	us-gaap	Net Income Loss NetIncomeLoss	-13039864
	us-gaap	Investment Income Interest InvestmentIncomeInterest	129120
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	362131
	us-gaap	Debt Instrument Increase Accrued Interest DebtInstrumentIncreaseAccruedInterest	2751378
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	118284
	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	713968
	us-gaap	Interest Expense InterestExpense	2834609
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10180271
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	68716
	us-gaap	Debt Instrument Periodic Payment Principal DebtInstrumentPeriodicPaymentPrincipal	813810
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-1658017
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-716786
	us-gaap	Interest Costs Incurred Capitalized InterestCostsIncurredCapitalized	0
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	114058
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-556967
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	256843
	us-gaap	Royalty Expense RoyaltyExpense	246280
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	11019468
	us-gaap	Proceeds From Sale Of Other Property Plant And Equipment ProceedsFromSaleOfOtherPropertyPlantAndEquipment	1750
	us-gaap	Costs And Expenses CostsAndExpenses	18901943
	us-gaap	Paid In Kind Interest PaidInKindInterest	-713968
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	49353851
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8475392
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	345474
	us-gaap	Share Based Compensation ShareBasedCompensation	2245565
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	105000
	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	919346
	us-gaap	Proceeds From Repayments Of Debt ProceedsFromRepaymentsOfDebt	-813810
	cris	Class Of Warrant Or Right Expiration Year And Month ClassOfWarrantOrRightExpirationYearAndMonth	2015-01
	cris	Common Stock Offering Cost Including Commission CommonStockOfferingCostIncludingCommission
	cris	Research And Development Revenue ResearchAndDevelopmentRevenue	-44672
	cris	Adjustments To Additional Paid In Capital Share Based Compensation Mark To Market On Stock Options To Non Employees AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationMarkToMarketOnStockOptionsToNonEmployees	37211
	cris	Proceeds From At Market Issuance Of Common Stock Net Of Issuance Costs ProceedsFromAtMarketIssuanceOfCommonStockNetOfIssuanceCosts	0
	cris	Available For Sale Securities Weighted Average Maturity AvailableForSaleSecuritiesWeightedAverageMaturity	P5M21D
	cris	Share Based Compensation Plans ShareBasedCompensationPlans	2	Plans
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	640000	shares
CY2014Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.09
CY2010Q1	cris	Proceeds From Registered Direct Offering Of Common Stock And Warrants Net Of Issuance Costs ProceedsFromRegisteredDirectOfferingOfCommonStockAndWarrantsNetOfIssuanceCosts	14942000
CY2013	cris	Available For Sale Securities Weighted Average Maturity AvailableForSaleSecuritiesWeightedAverageMaturity	P4M21D
CY2013Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	82456708	shares
CY2013Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.02
CY2013Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11905073	shares
CY2013Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	314106
CY2013Q3	us-gaap	Licenses Revenue LicensesRevenue	6000000
CY2013Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	130368
CY2013Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1862631
CY2013Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1998206
CY2013Q3	us-gaap	Royalty Revenue RoyaltyRevenue	1080233
CY2013Q3	us-gaap	Revenues Revenues	7202083
CY2013Q3	us-gaap	Net Income Loss NetIncomeLoss	-1867838
CY2013Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	39024
CY2013Q3	us-gaap	Interest Expense InterestExpense	964543
CY2013Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4170751
CY2013Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1072687
CY2013Q3	us-gaap	Royalty Expense RoyaltyExpense	54014
CY2013Q3	us-gaap	Costs And Expenses CostsAndExpenses	7071715
CY2013Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2846950
CY2013Q3	us-gaap	Share Based Compensation ShareBasedCompensation	922554
CY2013Q3	cris	Research And Development Revenue ResearchAndDevelopmentRevenue	121850
CY2014Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	86004857	shares
CY2014Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.06
CY2014Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12737636	shares
CY2014Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	91973
CY2014Q3	us-gaap	Licenses Revenue LicensesRevenue	0
CY2014Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-4753031
CY2014Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5584080
CY2014Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-827112
CY2014Q3	us-gaap	Royalty Revenue RoyaltyRevenue	1783271
CY2014Q3	us-gaap	Revenues Revenues	1764864
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	-5580143
CY2014Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	38881
CY2014Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	274661
CY2014Q3	us-gaap	Interest Expense InterestExpense	933903
CY2014Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3705365
CY2014Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-67910
CY2014Q3	us-gaap	Royalty Expense RoyaltyExpense	89295
CY2014Q3	us-gaap	Costs And Expenses CostsAndExpenses	6517895
CY2014Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2723235
CY2014Q3	us-gaap	Share Based Compensation ShareBasedCompensation	818300
CY2014Q3	cris	Research And Development Revenue ResearchAndDevelopmentRevenue	-18407
CY2014Q3	cris	Adjustments To Additional Paid In Capital Share Based Compensation Mark To Market On Stock Options To Non Employees AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationMarkToMarketOnStockOptionsToNonEmployees	37211

Files In Submission

Name	View Source	Status
0001193125-14-404759-index-headers.html	Edgar Link	pending
0001193125-14-404759-index.html	Edgar Link	pending
0001193125-14-404759.txt	Edgar Link	pending
0001193125-14-404759-xbrl.zip	Edgar Link	pending
cris-20140930.xml	Edgar Link	completed
cris-20140930.xsd	Edgar Link	pending
cris-20140930_cal.xml	Edgar Link	unprocessable
cris-20140930_def.xml	Edgar Link	unprocessable
cris-20140930_lab.xml	Edgar Link	unprocessable
cris-20140930_pre.xml	Edgar Link	unprocessable
d793244d10q.htm	Edgar Link	pending
d793244dex311.htm	Edgar Link	pending
d793244dex312.htm	Edgar Link	pending
d793244dex321.htm	Edgar Link	pending
d793244dex322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CRIS
CURIS INC Stock $cris

2014 Q4 Form 10-Q Financial Statement

#000119312514404759 Filed on November 10, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRIS CURIS INC Stock $cris

2014 Q4 Form 10-Q Financial Statement

#000119312514404759 Filed on November 10, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRIS
CURIS INC Stock $cris